Connect
MJA
MJA

Evaluating the chlamydia and gonorrhoea screening program in the Humanitarian Entrant Health Service, Western Australia

Veronica C Hoad and Aesen Thambiran
Med J Aust 2012; 197 (1): 47-49. || doi: 10.5694/mja11.10745
Published online: 2 July 2012

Chlamydia trachomatis and Neisseria gonorrhoeae are significant causes of sexually transmissible infections (STIs) worldwide,1 but there are limited data in the countries from which refugees originate to guide Australian screening of refugees for these diseases.

Before arrival, refugees being considered for Australian settlement undergo a limited health screen that includes screening for HIV and active tuberculosis (TB). Therefore, postarrival screening of refugees is essential to improve the health of the individual. The Humanitarian Entrant Health Service (HEHS) in Perth, Western Australia, aims to provide a free health assessment for refugees, including the recommended screening for infectious disease.2

The rationale for chlamydia and gonorrhoea screening is that failure to diagnose and treat patients with the diseases may result in transmission and significant complications, including pelvic inflammatory disease, ectopic pregnancy, infertility, conjunctivitis and pneumonia in newborn babies,3 and increased risk of HIV acquisition and transmission.4

The opportunistic screening guidelines for the general Australian population, as recommended by the Australasian Society for HIV Medicine (ASHM),5 compared with the separate Australian refugee screening guidelines recommended by the Australasian Society for Infectious Diseases (ASID),2 are outlined in Box 1. From 2006 to 2009, the HEHS offered chlamydia and gonorrhoea screening consistent with the ASID guidelines.

The aim of this study was to document the prevalence of chlamydia and gonorrhoea in the refugee population settling in WA; to determine the individual and population health benefit of screening; and to make recommendations on the future screening of chlamydia and gonorrhoea in the refugee population.

Methods

Demographic and clinical data for all refugees accepted by WA who presented for screening at the HEHS from 1 January 2006 to 31 December 2009 were entered into Medtech32 (Medtech Global, Auckland, New Zealand), a practice management software database used by the HEHS for all pathology test requests. All chlamydia and gonorrhoea tests were performed at PathWest Laboratory Medicine WA, Perth. Data for that period that we extracted from Medtech32 and entered into Microsoft Excel (Microsoft Corporation, Redmond, Wash, USA) included age and sex of refugees, country of origin and country of refuge, and requested polymerase chain reaction (PCR) tests for chlamydia and gonorrhoea.

The Western Australian Notifiable Infectious Diseases Database (WANIDD) is the WA statutory notification database that stores data on cases of chlamydia and gonorrhoea. Laboratory case data are transferred electronically to WANIDD, therefore it is a complete database of all laboratory cases of chlamydia and gonorrhoea diagnosed in the HEHS.

We extracted from WANIDD the chlamydia and gonorrhoea notifications for the period 1 January 2006 – 31 December 2009 to determine the number of chlamydia and gonorrhoea infections present in the HEHS population screened during that period.

We conducted a Cochran–Armitage trend test to examine if there was a significant trend of decreasing chlamydia prevalence with increasing age up to 39 years.

As a quality improvement study considered to be of negligible risk, our study was exempted from requiring ethics approval by the Sir Charles Gairdner Group Human Research Ethics Committee.

Results

Of an estimated 6222 refugees who settled in WA from 2006 to 20096 and were eligible for screening, 4762 (76%) responded to the invitation and underwent an HEHS assessment.

We restricted our study to participants aged 15 years and older, of whom there were 2812. Of this group, 2610 (93%) had a documented chlamydia and gonorrhoea PCR test of first-void urine. About 55% (1437/2610) were aged 15–29 years, and 20% (529/2610) were 40 years or older. Fifty-six percent were African refugees, 33% were South-East Asian and 8% were Middle Eastern. Of the 202 participants who did not have a PCR test, 58% were aged 15–17 years and 12% were aged 50 years or older.

Box 2 shows the number screened by sex, ethnicity and age range, and C. trachomatis prevalence. No gonorrhoea infections were detected in the 2610 patients screened. The overall prevalence of chlamydia was found to be 0.8% (21/2610). The prevalence of chlamydia remained low (range, 0.19%–1.23%) when analysed by sex, ethnicity and age. The Cochran–Armitage trend test did not show a significant trend of decreased chlamydia prevalence with increased age category from 20 to 39 years (Z = 0.7537, P = 0.451).

Discussion

These prevalence data provide a valuable population-based estimate of chlamydia and gonorrhoea infection in the refugee population settling in WA, with the strength of a high percentage of the population having been screened. These prevalence estimates are surprisingly low, given that poverty, social instability, mobility and lack of protection against sexual violence in the refugee population may facilitate STI transmission.2

The true prevalence of chlamydia infection in the Australian population is unknown. Recent estimates of women at low risk of infection include 3.4% for women aged 18–24 years attending general practices7 and 0.9% for women aged 18–35 years.8 The available data on disadvantaged populations and other subgroups (including people attending youth health centres, defence force staff, university attendees, backpackers, Indigenous people and prisoners) in Australia indicate a higher prevalence of chlamydia and gonorrhoea (between 5% and 20%) than was found in the refugee population we studied.9-13 Based on these data, the refugee population may have a similar or lower prevalence of chlamydia compared with the general Australian population, and has a considerably lower prevalence than certain other high-risk subgroups.

Estimates of chlamydia and gonorrhoea prevalence in the countries of origin of the refugee intake are limited and vary considerably.14-19 While acknowledging the limited data available for comparison, the refugee population group settling in WA appear to have a low prevalence of chlamydia and gonorrhoea when compared with published data on prevalence in the population and high-risk groups in potential countries of origin.

There are several factors that may have had an impact on the prevalence of chlamydia and gonorrhoea in the refugee population settling in WA. Government screening of visa applicants for HIV20 may exclude people at higher risk of STIs.

A recent new or casual sexual partner is a strong risk factor for having an STI.21 Culture, sex and migration pathway may influence sexual behaviours. Refugees who undergo processing off-shore, especially those who arrive in a family unit, may be unlikely to have had a recent new sexual partner during resettlement. This highlights the importance of taking an accurate, gender-appropriate and culturally appropriate sexual history in identifying refugees at risk of an STI who should subsequently be screened.

The proportion of refugees settling in different Australian states varies by ethnicity. During the study period, New South Wales had a higher proportion of refugees from Iraq compared with WA.22 Different refugee intakes by state could affect the generalisability of this study to refugee populations in other states.

Conclusions and recommendations

Chlamydia and gonorrhoea are not prevalent conditions in this cohort of refugees settling in WA. The low prevalence rates of chlamydia, especially in refugees aged over 40 years, suggest that the ASID guidelines recommending the screening of all adults should be updated.

If the ASHM guidelines on chlamydia and gonorrhoea screening were used as documented in Box 1, most chlamydial infections would be detected with less unnecessary testing. However, women aged 30–39 years are still at risk of complications from chlamydia, such as ectopic pregnancy and infertility. Prevalence estimates of chlamydia in refugees aged 30–39 years are not significantly lower than estimates for refugees aged 20–29 years. In addition, it is likely that their contact with the HEHS would be the first time many refugees would have been offered an STI screen. Therefore, in addition to the general Australian guidelines, we recommend considering routinely screening all refugees up to age 39 years.

Received 14 June 2011, accepted 20 October 2011

  • Veronica C Hoad1
  • Aesen Thambiran2

  • North Metropolitan Area Health Service, Perth, WA.



Acknowledgements: 

We thank Donna Mak, Mitchell Smith and David Whyatt for their review of the original manuscript and Dr Jianguo Xiao for his help with data analysis.

Competing interests:

No relevant disclosures.

  • 1. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: WHO, 2001. http://www.who.int/hiv/pub/sti/who_hiv_aids_2001.02.pdf (accessed Feb 2012).
  • 2. Murray R, Davis J, Krause V, et al; Australian Society for Infectious Diseases Writing Group. Diagnosis, management and prevention of infections in recently arrived refugees. Sydney: Dreamweaver Publishing, 2009. http://www.asid.net.au/images/Documents/Guidelines/RefugeeGuidelines.pdf (accessed Feb 2012).
  • 3. Peipert JF. Clinical practice. Genital chlamydial infections. New Engl J Med 2003; 349: 2424-2430.
  • 4. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75: 3-17.
  • 5. Sexual Health Society of Victoria. National management guidelines for sexually transmissible infections. Melbourne: SHSOV, 2008. http://mshc.org.au/Portals/6/NMGFSTI.pdf (accessed Feb 2012).
  • 6. Australian Government Department of Immigration and Citizenship. Settlers by calendar year of arrival by age on arrival [internet database]. Canberra: DIC, 2010. http://www.immi.gov.au/living-in-australia/delivering-assistance/settlement-reporting-facility/ (accessed Jan 2010).
  • 7. Walker J, Fairley CK, Bradshaw CS, et al. The difference in determinants of Chlamydia trachomatis and Mycoplasma genitalium in a sample of young Australian women. BMC Infect Dis 2011; 11: 35.
  • 8. Hocking JS, Willis J, Tabrizi S, et al. A chlamydia prevalence survey of young women living in Melbourne, Victoria. Sex Health 2006; 3: 235-240.
  • 9. Kang M, Rochford A, Johnston V, et al. Prevalence of Chlamydia trachomatis infection among ‘high risk’ young people in New South Wales. Sex Health 2006; 3: 253-254.
  • 10. Buhrer-Skinner M, Muller R, Menon A, Gordon R. Novel approach to an effective community-based chlamydia screening program within the routine operation of a primary healthcare service. Sex Health 2009; 6: 51-56.
  • 11. Watkins RE, Mak DB, Connelly C. Testing for sexually transmitted infections and blood borne viruses on admission to Western Australian prisons. BMC Public Health 2009; 9: 385.
  • 12. Panaretto KS, Lee HM, Mitchell MR, et al. Prevalence of sexually transmitted infections in pregnant urban Aboriginal and Torres Strait Islander women in northern Australia. Aust N Z J Obstet Gynaecol 2006; 46: 217-224.
  • 13. McDonagh P, Ryder N, McNulty AM, Freedman E. Neisseria gonorrhoeae infection in urban Sydney women: prevalence and predictors. Sex Health 2009; 6: 241-244.
  • 14. Clift S, Anemona A, Watson-Jones D, et al. Variations of HIV and STI prevalences within communities neighbouring new goldmines in Tanzania: importance for intervention design. Sex Transm Infect 2003; 79: 307-312.
  • 15. Kamali A, Quigley M, Nakiyingi J, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003; 361: 645-652.
  • 16. Ghazal-Aswad S, Badrinath P, Osman N, et al. Prevalence of Chlamydia trachomatis infection among women in a Middle Eastern community. BMC Womens Health 2004; 4: 3.
  • 17. Siemer J, Theile O, Larbi Y, et al. Chlamydia trachomatis infection as a risk factor for infertility among women in Ghana, West Africa. Am J Trop Med Hyg 2008; 78: 323-327.
  • 18. Pépin J, Deslandes S, Khonde N, et al. Low prevalence of cervical infections in women with vaginal discharge in west Africa: implications for syndromic management. Sex Transm Infect 2004; 80: 230-235.
  • 19. Okoror LE, Agbonlahor DE, Esumeh FI, Umolu PI. Prevalence of chlamydia in patients attending gynecological clinics in south eastern Nigeria. Afr Health Sci 2007; 7: 18-24.
  • 20. Australian Government Department of Immigration and Citizenship. Health requirement for permanent entry to Australia. Form 1071i. Canberra: DIAC, 2007. http://www.immi.gov.au/allforms/pdf/1071i.pdf (accessed Feb 2012)
  • 21. Goulet V, de Barbeyrac B, Raherison S, et al; CSF group. Prevalence of Chlamydia trachomatis: results from the first national population-based survey in France. Sex Transm Infect 2010; 86: 263-270.
  • 22. Australian Government Department of Immigration and Citizenship. Population flows: immigration aspects. Canberra: DIC, 2008. http://www.immi.gov.au/media/publications/statistics/popflows2006-7/title.pdf (accessed Feb 2012).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.